Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine Inc (HYPR) pioneers accessible MRI technology through its groundbreaking Swoop® Portable MR Imaging System, transforming diagnostic capabilities in critical care and underserved settings. This page serves as the definitive source for verified news and announcements related to corporate developments, clinical milestones, and financial performance.
Investors and healthcare professionals will find timely updates on regulatory clearances, partnership agreements, quarterly earnings, and technological advancements. Our curated collection includes press releases about device deployments, peer-reviewed study results, and strategic initiatives driving portable MRI adoption.
Key coverage areas include Swoop system innovations, financial results analysis, leadership updates, and market expansion efforts. All content is rigorously verified to ensure accuracy and relevance for stakeholders evaluating HYPR's position in the medical imaging sector.
Bookmark this page for streamlined access to Hyperfine's latest progress in redefining bedside diagnostics through ultra-low-field MRI technology. Check regularly for objective reporting on developments impacting both clinical practice and long-term corporate strategy.
Hyperfine (Nasdaq: HYPR) has announced the initiation of the PRIME (Portable Rapid Imaging for Medical Emergencies) study, enrolling its first patients at Yale School of Medicine. The study will evaluate the company's AI-powered Swoop® portable MRI system in emergency department settings.
The PRIME study expands upon the previous ACTION PMR study and will utilize the next-generation Swoop® system with Optive AI™ software, featuring enhanced image quality and sharper anatomical detail. The research aims to assess the technology's effectiveness as a triage tool for various brain-related emergency conditions in a Level 1 emergency department.
Led by Dr. Kevin Sheth and Dr. Adam De Havenon, the study focuses on addressing critical challenges in emergency departments, including patient boarding and limited MRI access. The initiative aligns with Hyperfine's strategy to drive commercial growth by demonstrating how portable MRI can improve clinical workflows and diagnostic access at the point of care.
Hyperfine (Nasdaq: HYPR), known for developing the Swoop® system - the first FDA-cleared AI-powered portable MRI system for brain imaging, has scheduled its Q2 2025 financial results announcement for August 13, 2025.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the live audio webcast and recording through Hyperfine's investor relations website. Participants are advised to register at least 15 minutes before the call.
Hyperfine (Nasdaq: HYPR) announced promising interim results from the CARE PMR study at the 2025 Alzheimer's Association International Conference. The study evaluated the company's Swoop® AI-powered portable MRI system for monitoring Alzheimer's patients receiving Lecanemab therapy.
The study of 31 Alzheimer's patients demonstrated 100% sensitivity in detecting ARIA-E (cerebral edema) when compared to clinical high-field MRI scans. The Swoop® system offers a potential solution to overcome barriers in MRI safety monitoring for amyloid-targeting therapies, providing an affordable, portable alternative at the point of care.
The research, funded by the Alzheimer's Association and American Society of Neuroradiology, suggests ultra-low-field MRI could serve as an effective triage tool, though high-field MRI may still be needed for comprehensive evaluation in some cases.
Hyperfine (NASDAQ: HYPR) announced significant progress in expanding the application of its Swoop® AI-powered portable MRI system for dementia care. The company highlighted two major developments: a new study at the University of Kansas Alzheimer's Disease Research Center exploring expedited dementia diagnosis, and upcoming data presentations at the 2025 Alzheimer's Association International Conference.
The University of Kansas study, led by Dr. Jeffrey Burns, introduces the Accelerated Clinical Evaluations for Alzheimer's Disease (ACE-AD) program, combining in-office MR imaging, cognitive testing, and blood biomarkers in a single nurse-led clinic visit. Additionally, researchers from Washington University School of Medicine will present interim results from the CARE PMR study evaluating Swoop® for ARIA-E monitoring.
The initiative aims to address the growing global dementia crisis, affecting over 57 million people worldwide, by improving accessibility to MRI technology in underserved and rural areas.
Hyperfine (NASDAQ:HYPR) has commenced the commercial launch of its Optive AI™ software for existing Swoop® portable MRI system customers. The FDA-cleared software, which received approval in May 2025, significantly enhances image quality through AI-powered improvements in noise cancellation, image acquisition, reconstruction, and post-processing.
The software upgrade is being rolled out to U.S. hospitals and neurology offices, with international availability in Canada, Australia, and New Zealand. Clinical feedback has been notably positive, with physicians reporting markedly improved resolution and faster FLAIR images, enabling expanded use beyond ICU to ER and outpatient settings.
The Optive AI™ software is fully compatible with first-generation Swoop® systems and requires no hardware modifications, allowing immediate access to next-generation image quality for current users.
Hyperfine (Nasdaq: HYPR) has announced its first commercial sales of the next-generation Swoop® Portable MR Imaging system, powered by Optive AI™ software. Two leading hospitals in the northeastern United States have purchased the units following recent FDA clearance, planning to deploy them in intensive care units and emergency departments.
The new Swoop® system features enhanced signal-to-noise ratio and, combined with Optive AI™ software, delivers improved image resolution, uniformity, and faster acquisition times. The system's patient-centric design makes it particularly suitable for pediatric, elderly, and anxious patients, advancing Hyperfine's mission to transform MRI accessibility.
Hyperfine (NASDAQ: HYPR) has received FDA clearance for its Optive AI™ software, a significant upgrade for its Swoop® system - the world's first FDA-cleared AI-powered portable MRI system for brain imaging. The tenth-generation software release delivers substantial improvements in image quality through enhanced AI algorithms that optimize noise cancellation, image acquisition, reconstruction, and post-processing.
Early clinical users reported image quality approaching that of conventional 1.5 tesla MRI scanners. The company plans to roll out the software to accounts in Q3 2025. This release represents one of two major technology milestones for 2025, supporting Hyperfine's growth strategy for expansion into new hospital sites and entry into the neurology office market.
Hyperfine (NASDAQ: HYPR), known for developing the Swoop® system - the first FDA-cleared AI-powered portable magnetic resonance brain imaging system, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5th at 4:20pm ET and will be available for in-person meetings on Wednesday, June 4th. Interested parties can schedule one-on-one meetings through their Jefferies representative.
FAQ
What is the current stock price of HYPERFINE (HYPR)?
What is the market cap of HYPERFINE (HYPR)?
